uniQure (NASDAQ:QURE) Director Sells $278,500.00 in Stock

Posted by Francis Steltz on Jun 20th, 2026

uniQure N.V. (NASDAQ:QURE – Get Free Report) Director Madhavan Balachandran sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $27.85, for a total value of $278,500.00. Following the completion of the transaction, the director owned 43,254 shares in the company, valued at $1,204,623.90. This represents a 18.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Madhavan Balachandran also recently made the following trade(s):

On Thursday, June 11th, Madhavan Balachandran sold 1,993 shares of uniQure stock. The stock was sold at an average price of $27.06, for a total value of $53,930.58.

uniQure Price Performance

NASDAQ:QURE opened at $46.29 on Friday. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $71.50. The stock’s fifty day moving average is $24.74 and its two-hundred day moving average is $22.20. The company has a market capitalization of $2.92 billion, a P/E ratio of -13.30 and a beta of 0.98. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. Equities analysts expect that uniQure N.V. will post -3.64 EPS for the current year.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

Positive Sentiment: The FDA’s feedback now appears to support a near-term biologics license application for AMT-130, increasing the odds of accelerated approval for Huntington’s disease and boosting sentiment around uniQure’s lead program. Reuters
Positive Sentiment: Barclays upgraded uniQure and raised its price target to $65 from $25, reflecting a more constructive view of the company after the FDA development. Benzinga
Positive Sentiment: uniQure also announced preliminary AMT-260 data in refractory mesial temporal lobe epilepsy, saying the treatment was generally well tolerated with no serious adverse events so far and early signs of biological activity. GlobeNewswire
Neutral Sentiment: Insider selling by a director and an executive has drawn attention, but the trades were disclosed and at least one was made under a pre-arranged 10b5-1 plan, so they are less likely to be interpreted as a fundamental warning sign.
Neutral Sentiment: Several articles argue the stock may still be undervalued after the FDA update, but those calls mostly reflect optimism already fueled by the regulatory news rather than a new company-specific catalyst. Yahoo Finance

Hedge Funds Weigh In On uniQure

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of uniQure by 15.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock worth $65,673,000 after acquiring an additional 152,417 shares in the last quarter. Aberdeen Group plc lifted its stake in uniQure by 25.1% during the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after purchasing an additional 738,897 shares during the last quarter. Quinn Opportunity Partners LLC acquired a new position in uniQure in the third quarter valued at approximately $6,281,000. Farallon Capital Management LLC increased its stake in uniQure by 3,935.7% in the third quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock valued at $32,979,000 after purchasing an additional 551,000 shares during the last quarter. Finally, Boone Capital Management LLC purchased a new position in uniQure in the third quarter valued at approximately $8,599,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on QURE shares. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $12.00 to $35.00 in a research report on Wednesday, March 11th. Stifel Nicolaus set a $28.00 target price on uniQure in a research note on Tuesday, May 5th. The Goldman Sachs Group raised their target price on uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a report on Thursday. Sanford C. Bernstein downgraded uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. Finally, Wolfe Research started coverage on shares of uniQure in a research note on Monday, February 23rd. They set a “peer perform” rating on the stock. Twelve analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $58.92.

Check Out Our Latest Report on QURE

About uniQure

(Get Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.